Siegel RL, Miller KD, Wagle NS, Jemal A. Most cancers statistics, 2023. CA Most cancers J Clin. 2023;73:17–48.
Srivastava S, Mohanty A, Nam A, Singhal S, Salgia R. Chemokines and NSCLC: rising function in prognosis, heterogeneity, and therapeutics. Semin Most cancers Biol. 2022;86:233–46.
Lahiri A, Maji A, Potdar PD, Singh N, Parikh P, Bisht B, et al. Lung most cancers immunotherapy: progress, pitfalls, and guarantees. Mol Most cancers. 2023;22:40.
Qian F, Yang W, Chen Q, Zhang X, Han B. Screening for early stage lung most cancers and its correlation with lung nodule detection. J Thorac Dis. 2018;10:S846–59.
Ettinger DS, Wooden DE, Aisner DL, Akerley W, Bauman JR, Bharat A, et al. NCCN Pointers® insights: non–small cell lung most cancers, model 2.2023: featured updates to the NCCN tips. J Natl Compr Most cancers Netw. 2023;21:340–50.
Wang M, Herbst RS, Boshoff C. Towards customized remedy approaches for non-small-cell lung most cancers. Nat Med. 2021;27:1345–56.
Wu F, Fan J, He Y, Xiong A, Yu J, Li Y, et al. Single-cell profiling of tumor heterogeneity and the microenvironment in superior non-small cell lung most cancers. Nat Commun. 2021;12:2540.
Piechotta V, Jakob T, Langer P, Monsef I, Scheid C, Estcourt LJ, et al. A number of drug mixtures of bortezomib, lenalidomide, and thalidomide for first‐line remedy in adults with transplant‐ineligible a number of myeloma: a community meta‐evaluation. Cochrane Database Syst Rev. 2019;2019:CD013487.
Lee JM, McNamee CJ, Toloza E, Negrao MV, Lin J, Shum E, et al. Neoadjuvant focused remedy in resectable NSCLC: present and future views. J Thorac Oncol. 2023;18:1458–77.
Bi H-L, Zhang X-L, Zhang Y-L, Xie X, Xia Y-L, Du J, et al. The deubiquitinase UCHL1 regulates cardiac hypertrophy by stabilizing epidermal development issue receptor. Sci Adv. 2020;6:eaax4826.
Li S, Tune Y, Wang Ok, Liu G, Dong X, Yang F, et al. USP32 deubiquitinase: mobile capabilities, regulatory mechanisms, and potential as a most cancers remedy goal. Cell Demise Discov. 2023;9:338.
Li Q, Ye C, Tian T, Jiang Q, Zhao P, Wang X, et al. The rising function of ubiquitin-specific protease 20 in tumorigenesis and most cancers therapeutics. Cell Demise Dis. 2022;13:434.
Paulding CA, Ruvolo M, Haber DA. The Tre2 (USP6) oncogene is a hominoid-specific gene. Proc Natl Acad Sci USA. 2003;100:2507–11.
Solar Y-L, Guan X-L, Zhang P, Li M-F, Zhang J, Solar L. Pol-miR-363-3p performs a major function within the immune protection of Japanese flounder Paralichthys olivaceus in opposition to bacterial and viral an infection. Fish Shellfish Immunol. 2020;104:439–46.
Sapmaz A, Berlin I, Bos E, Wijdeven RH, Janssen H, Konietzny R, et al. USP32 regulates late endosomal transport and recycling by way of deubiquitylation of Rab7. Nat Commun. 2019;10:1454.
Hertel A, Alves LM, Dutz H, Tascher G, Bonn F, Kaulich M, et al. USP32-regulated LAMTOR1 ubiquitination impacts mTORC1 activation and autophagy induction. Cell Rep. 2022;41:111653.
Pankratz N, Dumitriu A, Hetrick KN, Solar M, Latourelle JC, Wilk JB, et al. Copy quantity variation in familial Parkinson illness. PLoS ONE. 2011;6:e20988.
Ma Y, Tian S, He S, Chen Q, Wang Z, Xiao X, et al. The mechanism of motion of FXR1P-related miR-19b-3p in SH-SY5Y. Gene. 2016;588:62–8.
Jeong S, Oh JM, Oh Ok-H, Kim I-W. Differentially expressed miR-3680-5p is related to parathyroid hormone regulation in peritoneal dialysis sufferers. PLoS ONE. 2017;12:e0170535.
Nakae A, Kodama M, Okamoto T, Tokunaga M, Shimura H, Hashimoto Ok, et al. Ubiquitin particular peptidase 32 acts as an oncogene in epithelial ovarian most cancers by deubiquitylating farnesyl-diphosphate farnesyltransferase 1. Biochem Biophys Res Commun. 2021;552:120–7.
Hu W, Wei H, Li Ok, Li P, Lin J, Feng R. Downregulation of USP32 inhibits cell proliferation, migration and invasion in human small cell lung most cancers. Cell Prolif. 2017;50:e12343.
Chen S, Chen X, Li Z, Mao J, Jiang W, Zhu Z, et al. Identification of ubiquitin-specific protease 32 as an oncogene in glioblastoma and the underlying mechanisms. Sci Rep. 2022;12:6445.
Li J, Bo Y, Ding B, Wang L. Understanding the regulatory function of USP32 and SHMT2 within the development of gastric most cancers. Cell J. 2023;25:222–8.
Akhavantabasi S, Akman HB, Sapmaz A, Keller J, Petty EM, Erson AE. USP32 is an energetic, membrane-bound ubiquitin protease overexpressed in breast cancers. Mamm Genome. 2010;21:388–97.
Zhang H, Tao Y, Ding X, Wang Y, Wang X. Roles of the hsa_circ_0013880/USP32/Rap1b axis within the proliferation and apoptosis of acute myeloid leukemia cells. Acta Biochim Biophys Sin (Shanghai). 2023;55:382–93.
Liu C, Chen Z, Fang M, Qiao Y. MicroRNA let-7a inhibits proliferation of breast most cancers cell by downregulating USP32 expression. Transl Most cancers Res. 2019;8:1763–71.
Li C, Gao Z, Cui Z, Liu Z, Bian Y, Solar H, et al. Deubiquitylation of Rab35 by USP32 promotes the transmission of imatinib resistance by enhancing exosome secretion in gastrointestinal stromal tumours. Oncogene. 2023;42:894–910.
Kirk JA, Cheung JY, Feldman AM. Therapeutic focusing on of BAG3: contemplating its complexity in most cancers and coronary heart illness. J Clin Make investments. 2021;131:e149415.
Yuan Y, Jiang J-Y, Wang J-M, Solar J, Li C, Liu B-Q, et al. BAG3-positive pancreatic stellate cells promote migration and invasion of pancreatic ductal adenocarcinoma. J Cell Mol Med. 2019;23:5006–16.
Behl C. Breaking BAG: the co-chaperone BAG3 in well being and illness. Developments Pharm Sci. 2016;37:672–88.
Stürner E, Behl C. The function of the multifunctional BAG3 protein in mobile protein high quality management and in illness. Entrance Mol Neurosci. 2017;10:177.
Linder B, Klein C, Hoffmann ME, Bonn F, Dikic I, Kögel D. BAG3 is a damaging regulator of ciliogenesis in glioblastoma and triple-negative breast most cancers cells. J Cell Biochem. 2022;123:77–90.
De Marco M, Turco MC, Marzullo L. BAG3 in tumor resistance to remedy. Developments Most cancers. 2020;6:985–8.
Basile A, De Marco M, Festa M, Falco A, Iorio V, Guerriero L, et al. Improvement of an anti-BAG3 humanized antibody for remedy of pancreatic most cancers. Mol Oncol. 2019;13:1388–99.
Zhang Y, Wang J-H, Lu Q, Wang Y-J. Bag3 promotes resistance to apoptosis by way of Bcl-2 relations in non-small cell lung most cancers. Oncol Rep. 2012;27:109–13.
Liu C, Chen Z, Ding X, Qiao Y, Li B. Ubiquitin-specific protease 35 (USP35) mediates cisplatin-induced apoptosis by stabilizing BIRC3 in non-small cell lung most cancers. Lab Investig. 2022;102:524–33.
Zhang C, Tang Q, Xia H, Xu H, Bi F. PKM2 compensates for proteasome dysfunction by mediating the formation of the CHIP-HSP70-BAG3 advanced and the aggregation of ubiquitinated proteins. FASEB J. 2022;36:e22121.
Gao H, Yin J, Ji C, Yu X, Xue J, Guan X, et al. Focusing on ubiquitin particular proteases (USPs) in most cancers immunotherapy: from fundamental analysis to preclinical utility. J Exp Clin Most cancers Res. 2023;42:225.
Basar MA, Beck DB, Werner A. Deubiquitylases in developmental ubiquitin signaling and congenital ailments. Cell Demise Differ. 2021;28:538–56.
Zhang P, Li C, Li H, Yuan L, Dai H, Peng Z, et al. Ubiquitin ligase CHIP regulates OTUD3 stability and suppresses tumour metastasis in lung most cancers. Cell Demise Differ. 2020;27:3177–95.
Chitta Ok, Paulus A, Akhtar S, Blake MKK, Caulfield TR, Novak AJ, et al. Focused inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenström macroglobulinaemia tumour cells. Br J Haematol. 2015;169:377–90.
Qian M, Yan F, Wang W, Du J, Yuan T, Wu R, et al. Deubiquitinase JOSD2 stabilizes YAP/TAZ to advertise cholangiocarcinoma development. Acta Pharm Sin B. 2021;11:4008–19.
Xu P, Xiao H, Yang Q, Hu R, Jiang L, Bi R, et al. The USP21/YY1/SNHG16 axis contributes to tumor proliferation, migration, and invasion of non-small-cell lung most cancers. Exp Mol Med. 2020;52:41–55.
Fenteany G, Gaur P, Hegedűs L, Dudás Ok, Kiss E, Wéber E, et al. Multilevel construction–exercise profiling reveals a number of inexperienced tea compound households that every modulate ubiquitin-activating enzyme and ubiquitination by a definite mechanism. Sci Rep. 2019;9:12801.
Dou N, Hu Q, Li L, Wu Q, Li Y, Gao Y. USP32 promotes tumorigenesis and chemoresistance in gastric carcinoma through upregulation of SMAD2. Int J Biol Sci. 2020;16:1648–57.
Xiu M, Bao W, Wang J, Chen J, Li Y, Hai Y. Excessive USP32 expression contributes to most cancers development and is correlated with immune infiltrates in hepatocellular carcinoma. BMC Most cancers. 2023;23:1105.
Chandrasekaran AP, Kaushal Ok, Park C-H, Kim Ok-S, Ramakrishna S. USP32 confers most cancers cell resistance to YM155 through selling ER-associated degradation of solute service protein SLC35F2. Theranostics. 2021;11:9752–71.
Liao Q, Ozawa F, Friess H, Zimmermann A, Takayama S, Reed JC, et al. The anti-apoptotic protein BAG-3 is overexpressed in pancreatic most cancers and induced by warmth stress in pancreatic most cancers cell traces. FEBS Lett. 2001;503:151–7.
Brenner CM, Choudhary M, McCormick MG, Cheung D, Landesberg GP, Wang J-F, et al. BAG3: nature’s quintessential multi-functional protein capabilities as a ubiquitous intra-cellular glue. Cells. 2023;12:937.
De Marco M, Falco A, Iaccarino R, Raffone A, Mollo A, Guida M, et al. An rising function for BAG3 in gynaecological malignancies. Br J Most cancers. 2021;125:789–97.
Bao F, An S, Yang Y, Xu T-R. SODD promotes lung most cancers tumorigenesis by activating the PDK1/AKT and RAF/MEK/ERK signaling. Genes (Basel). 2023;14:829.
Liu P, Cong X, Liao S, Jia X, Wang X, Dai W, et al. International identification of phospho-dependent SCF substrates reveals a FBXO22 phosphodegron and an ERK-FBXO22-BAG3 axis in tumorigenesis. Cell Demise Differ. 2022;29:1–13.
Ullah R, Yin Q, Snell AH, Wan L. RAF-MEK-ERK pathway in most cancers evolution and remedy. Semin Most cancers Biol. 2022;85:123–54.
Guo Y-J, Pan W-W, Liu S-B, Shen Z-F, Xu Y, Hu L-L. ERK/MAPK signalling pathway and tumorigenesis. Exp Ther Med. 2020;19:1997–2007.
Hou J, Chen Q, Huang Y, Wu Z, Ma D. Caudatin blocks the proliferation, stemness and glycolysis of non-small cell lung most cancers cells by way of the Raf/MEK/ERK pathway. Pharm Biol. 2022;60:764–73.
Marchetti A, Felicioni L, Malatesta S, Grazia Sciarrotta M, Guetti L, Chella A, et al. Scientific options and final result of sufferers with non-small-cell lung most cancers harboring BRAF mutations. J Clin Oncol. 2011;29:3574–9.
Ghousein A, Mosca N, Cartier F, Charpentier J, Dupuy J-W, Raymond A-A, et al. miR-4510 blocks hepatocellular carcinoma improvement by way of RAF1 focusing on and RAS/RAF/MEK/ERK signalling inactivation. Liver Int. 2020;40:240–51.
Fan Q, Liang X, Xu Z, Li S, Han S, Xiao Y, et al. Pedunculoside inhibits epithelial-mesenchymal transition and overcomes Gefitinib-resistant non-small cell lung most cancers by way of regulating MAPK and Nrf2 pathways. Phytomedicine. 2023;116:154884.
Solar L, Yu J, Guinney J, Qin B, Sinicrope FA. USP10 regulates ZEB1 ubiquitination and protein stability to inhibit ZEB1-mediated colorectal most cancers metastasis. Mol Most cancers Res. 2023;21:578–90.
